Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28205136 | 0.73 | DAO (0.40) | MEN1ALDH1A1KMT2ACREBBPDAO | |
| SCHEMBL6185177 | 0.67 | IDO1 (0.57) | MEN1ALDH1A1KMT2ACREBBPBCHE | |
| SCHEMBL29636443 | 0.66 | BCHE (0.42) | MEN1ALDH1A1KMT2ACREBBPHTR5A | |
| SCHEMBL2587087 | 0.66 | BCHE (0.42) | MEN1ALDH1A1KMT2ACREBBPHTR5A | |
| Iodide SCHEMBL13386176 | 0.64 | BCHE (0.41) | MEN1ALDH1A1KMT2ACREBBPHTR5A | |
| SCHEMBL8471857 | 0.60 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2ACREBBPHTR5A | |
| Hydrochloric Acid SCHEMBL11306271 | 0.60 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2AHTR5ADAO | |
| SCHEMBL31331504 | 0.59 | NOX1 (0.61) | MEN1ALDH1A1KMT2ABCHECYP1A2 | |
| SCHEMBL2176289 | 0.59 | ALOX5 (0.35) | ALDH1A1KMT2ACYP1A2CYP2A6 | |
| SCHEMBL194062 | 0.59 | NOX1 (0.61) | MEN1ALDH1A1KMT2ABCHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | MEN1 1402/4885ALDH1A1 525/4885KMT2A 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.